Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 23, 2026 07:45 ET | Source: Dime Community Bancshares, Inc.

Dime Reports 10% Quarter-Over-Quarter Increase and 67% Year-Over-Year Increase in EPS

Dime Reports 10% Quarter-Over-Quarter Increase and 67% Year-Over-Year Increase in EPS
April 23, 2026 05:10 ET | Source: Novo Nordisk A/S

Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes

PIONEER TEENS is the first clinical trial of an oral GLP-1 in children & adolescents 10–17 years with type 2 diabetes, addressing a significant unmet need
April 20, 2026 16:00 ET | Source: Levi & Korsinsky, LLP

HTGC Investor Alert: Hercules Capital Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After CEO Allegedly Certified Misleading Statements: Levi & Korsinsky

NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP alerts investors in Hercules Capital, Inc. (NYSE: HTGC) of a pending securities class action naming two senior officers as...
April 20, 2026 08:32 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 20 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
April 20, 2026 08:00 ET | Source: AskBio Inc. (AskBio)

AskBio's Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s Disease

Berlin, Germany, and Durham, N.C., USA, April 20, 2026 (GLOBE NEWSWIRE) -- Not intended for UK Media Ametefgene parvec (AB-1005) manufactured at Viralgen commercial manufacturing facility...
April 20, 2026 05:19 ET | Source: Novo Nordisk A/S

Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease

Etavopivat showed a 27% reduction in vaso-occlusive crisis events and ~4-month delay to first vaso-occlusive crisis event on top of standard of care1Haemoglobin response was superior with...
April 15, 2026 13:33 ET | Source: Dime Community Bancshares, Inc.

Dime Announces Appointment of Meyer Eichler as Executive Vice President, Managing Executive Director

Dime Announces Appointment of Meyer Eichler as Executive Vice President, Managing Executive Director
April 15, 2026 08:30 ET | Source: Dime Community Bancshares, Inc.

Dime Announces Significant Hires to Advance Growth Plan

Dime Announces Significant Hires to Advance Growth Plan
April 14, 2026 08:00 ET | Source: Illume Fertility

Illume Fertility Launches “The Whole Story” Campaign for National Infertility Awareness Week 2026

Norwalk, CT, April 14, 2026 (GLOBE NEWSWIRE) -- In recognition of National Infertility Awareness Week (NIAW), April 19-25, Illume Fertility, a leading fertility practice in the tri-state area known...
April 14, 2026 07:00 ET | Source: Innventure, Inc.

Innventure to Host Operating Company CEO Call on April 27

ORLANDO, Fla., April 14, 2026 (GLOBE NEWSWIRE) -- Innventure, Inc. (NASDAQ: INV) (“Innventure”), an industrial growth conglomerate, today announced that it will host an operating company CEO call at...